Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis.
Momenta Pharmaceuticals Announces FDA Approval of ANDA for Glatopa(TM) (glatiramer acetate injection), the First Substitutable Generic for COPAXONE(R) (glatiramer acetate injection) 20mg
BRIEF-Health Canada approves Genzyme's Aubagio to treat relapsing remitting multiple sclerosis
Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson's disease.
Gustatory Dysfunction in Multiple Sclerosis
Ofatumumab Dose-finding in RRMS Patients
The majority of CD1d-sulfatide-specific T cells in human blood use a semiinvariant Vδ1 TCR.
Chemistry, toxicology, pharmacology and pharmacokinetics of idebenone: a review.
Cost-effectiveness analysis of interferon beta-1b as treatment for patients with clinically isolated syndrome suggestive of multiple sclerosis in Spain.
Determination and characterization of a cannabinoid receptor in rat brain.
A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects.
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.
Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey.
Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis.
FDA Accepts Filing of BETACONNECT™* for Relapsing-Remitting Multiple Sclerosis Patients Taking BETASERON® (interferon beta-1b)
Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis.
Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review.
Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects.
The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis.
Therapeutic class review, Neurological - multiple sclerosis dalfampridine (Ampyra(TM))
Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS.
Sphingosine and FTY720 are potent inhibitors of the transient receptor potential melastatin 7 (TRPM7) channels.
Late relapse of non-seminomatous testicular cancer during treatment of multiple sclerosis with interferon β-1a: A case report.

Pages